Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.
Lack of response to monoclonal antibodies (mAbs) has been associated with inadequate mAb serum concentrations. Therapeutic drug monitoring (TDM) of mAbs has the potential to guide to more effective dosing in individual patients. This review discusses the mechanisms responsible for interpatient variability of mAb pharmacokinetics, summarizes exposure-response data of mAbs used in inflammatory and malignant disease, presents current evidence of mAb-TDM in inflammatory disease, and provides hurdles and required future steps for further implementing mAb-TDM.
Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands.|Department of Clinical Pharmacy, Hospital Group Twente, Almelo-Hengelo, The Netherlands.
T H
TH
Oude Munnink
Department of Clinical Pharmacy, Hospital Group Twente, Almelo-Hengelo, The Netherlands.
M J
MJ
Henstra
BIOS Lab on a Chip Group, MESA+ Institute for Nanotechnology and MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, Enschede, The Netherlands.
L I
LI
Segerink
Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands.
K L L
KL
Movig
Department of Clinical Pharmacy, Hospital Group Twente, Almelo-Hengelo, The Netherlands.
P
P
Brummelhuis-Visser
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D054796:Drug Dosage Calculations; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D058990:Molecular Targeted Therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014409:Tumor Necrosis Factor-alpha